Pinto A, Ocanto A, Couñago F. Potential role of transmembrane 9 superfamily member 1 as a biomarker in urothelial cancer. World J Clin Oncol 2024; 15(8): 965-967 [PMID: 39193159 DOI: 10.5306/wjco.v15.i8.965]
Corresponding Author of This Article
Alvaro Pinto, PhD, Doctor, Department of Medical Oncology, University Hospital La Paz, Paseo Castellana 261, Madrid 28046, Spain. alvaropintomarin@gmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Aug 24, 2024; 15(8): 965-967 Published online Aug 24, 2024. doi: 10.5306/wjco.v15.i8.965
Potential role of transmembrane 9 superfamily member 1 as a biomarker in urothelial cancer
Alvaro Pinto, Abrahams Ocanto, Felipe Couñago
Alvaro Pinto, Department of Medical Oncology, University Hospital La Paz, Paseo Castellana 261, Madrid 28046, Spain
Abrahams Ocanto, Felipe Couñago, Department of Radiation Oncology, GenesisCare, Hospital Universitario San Francisco de Asís, Madrid 28002, Spain
Abrahams Ocanto, Felipe Couñago, Department of Radiation Oncology, GenesisCare, Vithas La Milagrosa University Hospital, Madrid 28010, Spain
Felipe Couñago, National Director GenesisCare, Madrid 28043, Spain
Author contributions: Pinto A contributed to the discussion and design of the manuscript; Pinto A, Ocanto A and Couñago F designed the overall concept, outline of the manuscript, contributed to the writing, and editing the manuscript and review of the literature; All authors contributed to this paper.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Alvaro Pinto, PhD, Doctor, Department of Medical Oncology, University Hospital La Paz, Paseo Castellana 261, Madrid 28046, Spain. alvaropintomarin@gmail.com
Received: January 11, 2024 Revised: June 15, 2024 Accepted: July 4, 2024 Published online: August 24, 2024 Processing time: 218 Days and 1.2 Hours
Abstract
Bladder cancer is a urological tumor with high rates of recurrence despite recent advances in novel therapies. Many proteins involved in the molecular mechanisms are currently an enigma, especially the transmembrane 9 superfamily member 1 which has an unclear function. Wei et al published the function and mechanism of this protein, and showed that it could participate in the proliferation, migration and invasion of tumor cells in bladder cancer, therefore treatments directed against this protein may be beneficial in avoiding this condition.
Core Tip: The overexpression of transmembrane 9 superfamily member 1 promotes cells into the gap 2/mitosis phase of the cell cycle and has a role in autophagy and immune-mediated mechanisms, therefore, the potential inhibition of transmembrane 9 superfamily member 1 or related pathways could result in antitumoral activity, providing a new target in the treatment of patients with bladder cancer.
